Influence of the inflammatory response on treatment of hepatitis C with triple therapy
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Chronic hepatitis C is a leading cause of liver disease. Infection triggers an immediate immune response in the host that is mediated by humoral/cellular mechanisms. T cells respond to infection via secretion of cytokines, which inhibit or stimulate one another, leading to cytokine imbalance and ultimately affecting treatment. Studies using interferon (IFN) and ribavirin (RBV) showed that TCD8+ cells and cytokine levels are associated with sustainable virological response (SVR). However, studies that investigated the effects of triple therapy (TT) are limited. METHODS: The study included hepatitis C virus (HCV)+ RNA, naives, genotype 1, ≥18 years, and advanced fibrosis (F≥3) patients. Samples were collected at baseline and after 12 weeks (W12) of TT. Six cytokines were analyzed by flow cytometry. RESULTS: Of 31 patients, four were excluded (two deaths, one interrupted TT, and one F2 patient). Of the 27 remaining patients, 21 (78%) were cirrhotic. SVR was achieved in 63% of the patients. The patients had a mean age of 55.11 ± 10.03 years. Analyses at baseline showed that the chemokine CCL5/Regulated on Activation, Normal T Cell Expressed and Secreted (RANTES) (p=0.04) and interleukin (IL)-6 (p=0.02), which was associated with SVR. RANTES (p=0.04) and IL-8 (p=0.01) levels were associated with SVR at W12. CONCLUSIONS: Similar to patterns observed during double therapy, IL-6, IL-8, and RANTES levels were associated with SVR in TT, indicating the potential role of interferon in immune response to hepatitis C virus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The treatment of physical disorders, e.g., interferon-based or virostatic treatments for hepatitis C (167, 197), chemotherapy for the treatment of cancer (168), surgery (169) or transplantation (170), can lead to additional cytokine release.”
From Cytokine Research in Depression: Principles, Challenges, and Open Questions (2019) · cites this paper as [167]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
An Algorithm for the Grading of Activity in Chronic Hepatitis C
Bedossa, P., & Poynard, T. (1996) · Hepatology · doi:10.1002/hep.510240201 · Cited by 4,088
Global epidemiology and genotype distribution of the hepatitis C virus infection
Gower, E., Estes, C., Blach, S., Razavi-Shearer, K., & Razavi, H. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.07.027 · Cited by 1,903
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
Bacon, B. R., Gordon, S. C., Lawitz, E., Marcellin, P., Vierling, J. M., Zeuzem, S., Poordad, F., Goodman, Z. D., Sings, H. L., Boparai, N., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009482 · Cited by 1,626
Telaprevir for Retreatment of HCV Infection
Zeuzem, S., Andreone, P., Pol, S., Lawitz, E., Diago, M., Roberts, S., Focaccia, R., Younossi, Z., Foster, G. R., Horban, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013086 · Cited by 1,546
Zimmermann, H. W., Seidler, S., Gassler, N., Nattermann, J., Luedde, T., Trautwein, C., & Tacke, F. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021381 · Cited by 276
Polyak, S. J., Khabar, K. S. A., Rezeiq, M., & Gretch, D. R. (2001) · Journal of Virology · doi:10.1128/jvi.75.13.6209-6211.2001 · Cited by 243
Nelson, D. R., Tu, Z., Soldevila-Pico, C., Abdelmalek, M., Zhu, H., Xu, Y. L., Cabrera, R., Liu, C., & Davis, G. L. (2003) · Hepatology · doi:10.1002/hep.1840380412 · Cited by 202
The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection
Zeremski, M., Petrovic, L. M., & Talal, A. H. (2007) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2006.00838.x · Cited by 188
Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C
Butera, D., Marukian, S., Iwamaye, A. E., Hembrador, E., Chambers, T. J., Di Bisceglie, A. M., Charles, E. D., Talal, A. H., Jacobson, I. M., Rice, C. M., et al. (2005) · Blood · doi:10.1182/blood-2005-01-0126 · Cited by 178
Cited by
Cytokine Research in Depression: Principles, Challenges, and Open Questions
Himmerich, H., Patsalos, O., Lichtblau, N., Ibrahim, M. A. A., & Dalton, B. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00030 · Cited by 313
Braz, A. M. M., Winckler, F. C., Binelli, L. S., Chimeno, L. G., Lopes, L. B. M., Lima, R. S., Simões, R. P., Grotto, R. M. T., Golim, M. D. A., & Silva, G. F. (2021) · Clinical and Experimental Medicine · doi:10.1007/s10238-021-00708-w · Cited by 3
“At the beginning of the disease, when there is still no fibrosis, cells of the immune system are recruited to the site of infection, and secretion of proinflammatory cytokines occurs [4, 45].”
BackgroundSelf-citation
Metadata
- Authors
- Winckler, F. C., Braz, A. M. M., Silva, V. N. D., Golim, M. D. A., Andrade, V. G. D., Machado, P. E. D. A., Silveira, L. V. D. A., & Silva, G. F.
- Affiliations
- Universidade Estadual Paulista (Unesp) (BR)
- Universidade Estadual Paulista, Brazil
- Venue
- Revista da Sociedade Brasileira de Medicina Tropical
- Publisher
- FapUNIFESP (SciELO)
- Published
- 2018-12
- Volume
- 51
- Issue
- 6
- Pages
- 731-736
- ISSN
- 0037-8682 (ISSN-L)
- 1678-9849
- OpenAlex
- W2902808860
- Cited by
- 2
- References
- 48
- Citations by year
- 2021: 1 · 2019: 1
- FWCI
- 0.32
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by
- Locations
- Revista da Sociedade Brasileira de Medicina Tropical (publishedVersion, cc-by)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Americanae (AECID Library) (submittedVersion, other-oa)
- Americanae (AECID Library) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Health Sciences › Medicine › Gastroenterology › Helicobacter pylori-related gastroenterology studies
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- chronic hepatitis C, triple therapy, interferon, ribavirin, cytokines, RANTES, interleukin-6, interleukin-8, sustained virological response, T cell response, advanced liver fibrosis, liver cirrhosis, HCV genotype 1
- MeSH terms
- Antiviral Agents, Drug Therapy, Combination, Female, Flow Cytometry, Genotype, Humans, Male, Middle Aged, Oligopeptides, Proline, Prospective Studies, Cytokines, Treatment Outcome, Viral Load, Hepatitis C, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Influence of the inflammatory response on treatment of hepatitis C with triple therapy. https://app.cochat.ai/papers/10.1590/0037-8682-0137-2018
- The paper
- Winckler, F. C., Braz, A. M. M., Silva, V. N. D., Golim, M. D. A., Andrade, V. G. D., Machado, P. E. D. A., Silveira, L. V. D. A., & Silva, G. F. (2018). Influence of the inflammatory response on treatment of hepatitis C with triple therapy. Revista da Sociedade Brasileira de Medicina Tropical. https://doi.org/10.1590/0037-8682-0137-2018
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.